샘플 요청 목록

 카트 문의
시장보고서
상품코드
1857357

세계의 약물 용출 스텐트(DES) 시장

Drug-Eluting Stents
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 189 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 약물 용출 스텐트(DES) 시장은 2030년까지 117억 달러에 도달

2024년에 83억 달러로 추정되는 약물 용출 스텐트(DES) 세계 시장은 2024-2030년간 CAGR 5.8%로 성장하여 2030년에는 117억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 폴리머 프리 코팅은 CAGR 6.0%를 나타내고, 분석 기간 종료시에는 79억 달러에 이를 것으로 예측됩니다. 폴리머 기반 코팅 부문의 성장률은 분석 기간중 CAGR 5.2%로 추정됩니다.

미국 시장은 22억 달러로 추정, 중국은 CAGR 9.5%로 성장 예측

미국의 약물 용출 스텐트(DES) 시장은 2024년에는 22억 달러에 이를 것으로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년 CAGR 9.5%로 성장하여 2030년에는 시장 규모 26억 달러에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.9%와 6.2%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.1%를 보일 것으로 예측됩니다.

세계의 약물 용출 스텐트(DES) 시장 - 주요 동향과 성장요인 정리

약물 용출 스텐트(DES)는 무엇인가?

약물 용출 스텐트(DES)는 플라크 축적으로 인한 관상동맥 협착을 특징으로 하는 관상동맥질환(CAD) 치료에 사용되는 특수 의료기기입니다. 이 스텐트는 동맥이 다시 막히는 재협착을 방지하기 위해 점진적으로 방출되는 약물로 코팅된 작은 메쉬 튜브로, 동맥이 다시 막히는 재협착을 방지합니다. 약물 용출 스텐트(DES)의 구조는 동맥을 기계적으로 지지하는 금속 비계와 시간이 지남에 따라 약물의 방출을 제어하는 폴리머 코팅이 포함되어 있습니다. 약물은 세포 증식을 억제하고 염증을 억제하는데, 이는 재협착을 예방하는 데 중요한 요소입니다. DES는 기계적 접근과 약리학적 접근을 결합하여 구조적 지지만을 제공하는 베어 메탈 스텐트(BMS)에 비해 재협착률이 높고, 재협착률이 더 높다는 단점을 보완합니다.

기술 발전으로 약물 용출 스텐트(DES)가 어떻게 개선되었습니까?

약물 용출 스텐트(DES) 분야에서는 약제 용출 스텐트의 효과와 안전성 프로파일을 향상시키는 놀라운 기술적 진보가 이루어지고 있습니다. 더 얇은 지지대 및 더 유연한 재료와 같은 스텐트 설계의 혁신은 스텐트의 전달 및 적합성을 개선하여 복잡한 동맥 경로를 쉽게 통과할 수 있도록 했습니다. 약물 전달 후 서서히 용해되는 생분해성 폴리머의 개발로 영구적인 폴리머 잔류에 따른 장기적인 합병증이 감소했습니다. 약물 제제의 발전도 중요한 역할을 하고 있으며, 새로운 약물은 세포 증식과 염증을 더 잘 조절할 수 있게 되었습니다. 혈관 내 초음파(IVUS), 광간섭단층촬영(OCT) 등의 영상 기술은 동맥의 실시간 고해상도 영상을 제공하여 스텐트의 정확한 삽입과 최적의 확장을 보장함으로써 스텐트 삽입 과정을 더욱 정교하게 만들어 줍니다. 이러한 기술적 개선은 전반적으로 환자의 예후를 개선하고, 부작용 발생률과 재수술의 필요성을 감소시킵니다.

약물 용출 스텐트(DES)의 임상 적용 및 장점은 무엇인가?

약물 용출 스텐트(DES)는 주로 관상동맥 질환의 치료에 사용되지만, 다른 혈관 질환에도 적용되고 있습니다. DES는 말초동맥질환(PAD) 관리에도 사용되며, 다리의 좁아진 동맥을 열어 혈류를 촉진하고 통증과 피로 등의 증상을 완화합니다. 당뇨병 및 다발성 병변과 같은 복잡한 병변의 치료에 DES의 사용은 유망한 결과를 보여 주었으며, 외과적 개입에 대한 보다 안전하고 효과적인 대안이 될 수 있습니다. DES의 주요 장점은 재협착의 위험이 낮고, 반복적인 혈관 재건술의 필요성이 감소하며, 환자의 장기적인 예후가 개선된다는 점입니다. 또한, 스텐트 삽입술은 최소 침습적이기 때문에 개심술에 비해 입원 기간이 짧고 회복이 빨라 많은 환자와 의료진이 선호하고 있는 시술입니다.

약물 용출 스텐트(DES) 시장의 성장 원동력은 무엇인가?

약물 용출 스텐트(DES) 시장의 성장은 기술 발전, 심혈관 질환의 유병률 증가, 의료 인프라 확대 등 여러 요인에 의해 이루어집니다. 생활습관의 변화와 고령화의 영향으로 관상동맥질환의 발병률이 증가하면서 DES와 같은 효과적인 치료 옵션에 대한 수요가 크게 증가하고 있습니다. 생체적합성 및 약물 전달 메커니즘을 강화한 차세대 스텐트 개발 등 스텐트 기술 개발이 시장 성장을 견인하고 있습니다. 또한, 환자와 의료 서비스 제공업체 사이에서 최소침습적 시술에 대한 선호도가 높아짐에 따라 기존 수술적 방법보다 DES의 채택이 증가하고 있습니다. 규제 당국의 승인과 유리한 상환 정책도 시장 확대에 중요한 역할을 하고 있습니다. 또한, 주요 산업 기업들의 R&D 투자 증가와 신흥 시장에서의 의료시설 확대는 새로운 성장 기회를 창출하고 있습니다. 첨단 영상처리 기술과 스텐트 삽입술의 통합은 임상 결과를 개선하고, 심혈관 치료 프로토콜에서 DES의 사례를 더욱 공고히 하고 있습니다. 이러한 요인들은 심장 건강에 대한 인식이 높아지고 심혈관 질환에 대한 적극적인 관리와 함께 약물 용출 스텐트(DES) 시장의 강력한 성장을 견인하고 있습니다.

부문

코팅(폴리머 프리, 폴리머 기반);용도(관상동맥 질환, 말초동맥 질환);최종 용도(심장병 센터, 외래수술센터(ASC), 병원)

조사 대상 기업 예

  • Abbott Laboratories
  • AlviMedica
  • Arterius Limited
  • Biotronik SE
  • Boston Scientific Corporation
  • Cook Medical
  • Medtronic plc
  • STENTYS SA
  • Terumo Corporation

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.11.10

Global Drug-Eluting Stents Market to Reach US$11.7 Billion by 2030

The global market for Drug-Eluting Stents estimated at US$8.3 Billion in the year 2024, is expected to reach US$11.7 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Polymer-Free Coating, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$7.9 Billion by the end of the analysis period. Growth in the Polymer-based Coating segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 9.5% CAGR

The Drug-Eluting Stents market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Drug-Eluting Stents Market - Key Trends and Drivers Summarized

What Are Drug-Eluting Stents and How Do They Function?

Drug-eluting stents (DES) are specialized medical devices used to treat coronary artery disease (CAD), a condition characterized by the narrowing of coronary arteries due to plaque buildup. These stents are tiny mesh tubes coated with medication that is gradually released to prevent the artery from becoming blocked again, a process known as restenosis. The structure of a drug-eluting stent includes a metal scaffold to provide mechanical support to the artery, and a polymer coating that controls the release of the drug over time. The drug inhibits cell proliferation and reduces inflammation, which are critical factors in preventing restenosis. By combining mechanical and pharmacological approaches, DES offer a significant improvement over bare-metal stents (BMS), which only provide structural support and are associated with higher rates of restenosis.

How Have Technological Advancements Improved Drug-Eluting Stents?

The field of drug-eluting stents has seen remarkable technological advancements that have enhanced their efficacy and safety profiles. Innovations in stent design, such as thinner struts and more flexible materials, have improved the deliverability and conformability of the stents, allowing for easier navigation through complex arterial pathways. The development of biodegradable polymers, which gradually dissolve after delivering the drug, has reduced long-term complications associated with permanent polymer residues. Advances in drug formulations have also played a crucial role, with newer drugs offering better control over cell proliferation and inflammation. Imaging technologies, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have further refined the deployment process by providing real-time, high-resolution images of the arteries, ensuring precise placement and optimal expansion of the stents. These technological improvements collectively contribute to better patient outcomes, reducing the incidence of adverse events and the need for repeat interventions.

What Are the Clinical Applications and Benefits of Drug-Eluting Stents?

Drug-eluting stents are primarily used in the treatment of coronary artery disease, but their applications extend to other vascular conditions as well. They are employed in the management of peripheral artery disease (PAD), where they help to open narrowed arteries in the legs, enhancing blood flow and reducing symptoms like pain and fatigue. The use of DES in treating complex lesions, such as those in patients with diabetes or multivessel disease, has shown promising results, offering a safer and more effective alternative to surgical interventions. The primary benefits of DES include a lower risk of restenosis and reduced need for repeat revascularization procedures, leading to improved long-term patient outcomes. Additionally, the minimally invasive nature of stent implantation, combined with shorter hospital stays and faster recovery times compared to open-heart surgery, makes DES a preferred option for many patients and healthcare providers.

What Drives the Growth in the Drug-Eluting Stents Market?

The growth in the drug-eluting stents market is driven by several factors, including technological advancements, increasing prevalence of cardiovascular diseases, and expanding healthcare infrastructure. The rising incidence of coronary artery disease, partly due to lifestyle changes and an aging population, is significantly boosting the demand for effective treatment options like DES. Advances in stent technology, such as the development of next-generation stents with enhanced biocompatibility and drug delivery mechanisms, are propelling market growth. Additionally, the growing preference for minimally invasive procedures among patients and healthcare providers is driving the adoption of DES over traditional surgical methods. Regulatory approvals and favorable reimbursement policies are also playing a crucial role in expanding the market reach. Furthermore, increasing investments in research and development by key industry players and the expansion of healthcare facilities in emerging markets are creating new opportunities for growth. The integration of advanced imaging technologies with stent deployment procedures is improving clinical outcomes, further strengthening the case for DES in cardiovascular treatment protocols. These factors, combined with a greater awareness of heart health and proactive management of cardiovascular conditions, are driving the robust growth of the drug-eluting stents market.

SCOPE OF STUDY:

The report analyzes the Drug-Eluting Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Coating (Polymer-Free, Polymer-based); Application (Coronary Artery Disease, Peripheral Artery Disease); End-Use (Cardiology Centers, Ambulatory Surgery Centers, Hospitals)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

  • Abbott Laboratories
  • AlviMedica
  • Arterius Limited
  • Biotronik SE
  • Boston Scientific Corporation
  • Cook Medical
  • Medtronic plc
  • STENTYS SA
  • Terumo Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Drug-Eluting Stents - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Advancements in Stent Design Propel Growth in Drug-Eluting Stents Market
    • Increasing Prevalence of Cardiovascular Diseases Expands Addressable Market Opportunity
    • Innovations in Biodegradable Polymers Strengthen Business Case for Next-Generation Stents
    • Advances in Drug Formulations Enhance Efficacy and Reduce Complications
    • Growing Geriatric Population Generates Increased Demand for Cardiovascular Treatments
    • Trends in Personalized Medicine and Patient-Specific Solutions Propel Market Growth
    • Expansion of Healthcare Infrastructure in Emerging Markets Creates New Opportunities
    • Integration of Imaging Technologies and Stent Deployment Techniques Improves Outcomes
    • Focus on Long-Term Patient Outcomes and Reduced Restenosis Rates Sustains Growth
    • Adoption of Advanced Manufacturing Processes Enhances Stent Quality and Performance
    • Development of Dual Therapy Stents and Combination Products Generates New Market Segments
    • Impact of Lifestyle Changes and Risk Factors on Cardiovascular Health Drives Market Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Drug-Eluting Stents Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Drug-Eluting Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Polymer-Free by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Polymer-Free by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Polymer-Free by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Polymer-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Coronary Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Coronary Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Coronary Artery Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Peripheral Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Peripheral Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Peripheral Artery Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cardiology Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cardiology Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Cardiology Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • JAPAN
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • CHINA
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • EUROPE
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Drug-Eluting Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • FRANCE
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • GERMANY
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Drug-Eluting Stents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • INDIA
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Drug-Eluting Stents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Drug-Eluting Stents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
  • AFRICA
    • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제